Abcam joins the Innovative Health Initiative LIGAND-AI project to advance artificial intelligence (AI)-driven drug discovery through open science

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Abcam serves 750,000 researchers in over 130 countries to help them reach results faster in areas like cancer, neurological disorders, infectious diseases, and metabolic disorders

  80% confidence

• LIGAND-AI aims to change drug discovery by combining advanced laboratory technologies with computational methods to create a seamless pipeline from experiment to prediction, generating billions of data points

  80% confidence

• The project brings together scientists and companies from across disciplines within an open science ecosystem, with diverse scientific communities coalescing around a common vision to generate and share valuable chemical data openly with the world

  80% confidence

• LIGAND-AI represents the next frontier in drug discovery, combining cutting-edge AI with large-scale experimental science to build predictive models that will unlock thousands of new targets

  80% confidence

• The project represents a major step toward the mission of Target 2035 to discover chemical modulators for every human protein by the year 2035

  80% confidence